The role of CXC and CC chemokines in patients with uveal melanoma

Myakoshina E.B.; Kulikova I.G.; Balatskaya N.V.; Katargina L.A.; Saakyan S.V.

doi:https://doi.org/10.17116/oftalma202113704131

Myakoshina E.B.

Helmholtz National Medical Research Center of Eye Diseases

ORCID: 0000-0002-2087-7155

Kulikova I.G.

Helmholtz National Medical Research Center of Eye Diseases

Balatskaya N.V.

Helmholtz National Medical Research Center of Eye Diseases

ORCID: 0000-0001-8007-6643

Katargina L.A.

Helmholtz National Medical Research Center of Eye Diseases

ORCID: 0000-0002-4857-0374

Saakyan S.V.

Helmholtz National Medical Research Center of Eye Diseases

ORCID: 0000-0001-8591-428X

The role of CXC and CC chemokines in patients with uveal melanoma

Authors:

Myakoshina E.B., Kulikova I.G., Balatskaya N.V., Katargina L.A., Saakyan S.V.

More about the authors

Journal: Russian Annals of Ophthalmology. 2021;137(4): 31‑37

DOI: 10.17116/oftalma202113704131

Read: 2057 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Myakoshina EB, Kulikova IG, Balatskaya NV, Katargina LA, Saakyan SV. The role of CXC and CC chemokines in patients with uveal melanoma. Russian Annals of Ophthalmology. 2021;137(4):31‑37. (In Russ.)
https://doi.org/10.17116/oftalma202113704131

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)

Использование инфографики авторами научных работ

Close metadata

PURPOSE

To study the role of chemokines of classes CXC and CC in blood serum and tear fluid of patients with uveal melanoma.

MATERIAL AND METHODS

The study included 118 people aged 53.7±12.2 years, among them 80 patients with uveal melanoma and 38 healthy donors. Group 1 included 32 patients with small tumors, group 2 (medium-sized tumors) — 26 patients; group 3 (large tumors) was comprised of 22 patients. Chemokines of classes CC (CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β, CCL5/RANTES, CCL11/Eotaxin) and CXC (CXCL1/GRO-α, CXCL8/IL-8, CXCL10/IP-10, CXCL12/SDF-1α) were determined by multiplex analysis of the blood serum and tear fluid. Statistical processing: Student’s t-test, Fisher criteria, and Pierson’s chi-squared test (χ2), differences were considered significant at p<0.05.

RESULTS

Significantly increased level of chemokines with pro-inflammatory (CCL5/RANTES), proliferative (CXCL10/IP-10) and pro-angiogenic (CXCL12/SDF-1α) effects was found in the blood serum of patients with small-sized uveal melanoma in comparison with healthy donors. Concentration of all studied pro-inflammatory, proliferative, and pro-angiogenic chemokines in the lacrimal fluid was found to be significantly elevated in both the affected and the paired “healthy” eyes in all 3 groups of patients, with the maximum content seen in the large tumor group.

CONCLUSION

The obtained data indicates that early local and systemic immune imbalance can be observed in uveal melanoma, and detection of chemokines can serve as a good reason for developing targeted therapy for small uveal melanoma.

Keywords:

uveal melanoma

chemokines in blood serum and tear fluid

Authors:

Myakoshina E.B.

Helmholtz National Medical Research Center of Eye Diseases

ORCID: 0000-0002-2087-7155

Kulikova I.G.

Helmholtz National Medical Research Center of Eye Diseases

Balatskaya N.V.

Helmholtz National Medical Research Center of Eye Diseases

ORCID: 0000-0001-8007-6643

Katargina L.A.

Helmholtz National Medical Research Center of Eye Diseases

ORCID: 0000-0002-4857-0374

Saakyan S.V.

Helmholtz National Medical Research Center of Eye Diseases

ORCID: 0000-0001-8591-428X

Received:

24.06.2020

Accepted:

06.09.2020

Close metadata

References:

Mantovani A. Chemokines in neoplastic progression. Semin Cancer Biol. 2004;14:147-148. https://doi.org/10.1016/j.semcancer.2003.10.010
Bacon K, Baggiolini M, Broxmeyer H, Horuk R, Lindley I, Mantovani A, Maysushima K, Murphy P, Nomiyama H, Oppenheim J, Rot A, Schall T, Tsang M, Thorpe R, van Damme J, Wadhwa M, Yoshie O, Zlotnik A, Zoon K. Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res. 2002;22:1067-1068. https://doi.org/10.1089/107999002760624305
Karagodin VP, Mel’nichenko AA, Orekhov AN. Chemokine proteins: a role in carcinogenesis and inflammation. Patogenez. 2015;13(4):28-33. (In Russ.).
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30:1073-1081. https://doi.org/10.1093/carcin/bgp127
Arsentieva NA, Semenov AV, Zhebrun DA, Vasilyeva EV, Totolyan Areg A. Role of CXCR3 chemokine receptor and its ligands in certain diseases. Meditsinskaya immunologiya. 2019;21(4):617-632. (In Russ.). https://doi.org/10.15789/1563-0625-2019-4-617-632
Likhvantseva VG. The disturbances in IL-8 production in patients with uveal melanoma. Meditsinskaya immunologiya. 2000;2(3):305-310. (In Russ.).
Ejaeidi AA, Craft BS, Puneky LV, Lewis RE, Cruse JM. Hormone receptor-independent CXCL10 production is associated with the regulation of cellular factors linked to breast cancer progression and metastasis. Exp Mol Pathol. 2015;99(1):163-172. https://doi.org/10.1016/j.yexmp.2015.06.002
Gratchev A, Kzhyshkowska J, Utikal J, Goerdt S. Interleukin-4 and dexamethasone counterregulate extracellular matrix remodeling and phagocytosis in type-2 macrophages. Scand J Immunol. 2005;61:10-17. https://doi.org/10.12691/ajidm-3-2-4
Saakyan SV, Balatskaya NV, Katargina LA, Kulikova IG, Myakoshina EB. Subpopulation profile of peripheral blood lymphocytes in uveal melanoma. Meditsinskaya immunologiya. 2019;21(4):765-772. (In Russ.). https://doi.org/10.15789/1563-0625-2019-4-765-772
Saakyan SV, Myakoshina EB, Krichevskaya GI, Slepova OS, Panteleeva OG, Andryushin AS, Khoroshilova-Maslova IP, Zakharova GP. Examination of patients with uveal melanoma for the presence of herpes viral infection. Voprosy virusologii. 2016;61(6):284-287. (In Russ.). https://doi.org/10.18821/0507-4088-2016-61-6-284-287
Saakyan SV, Zakharova G.P., Myakoshina E.B. Mast cells in the microenvironment of uveal melanoma. Arkhiv patologii. 2019;81(6):63-70. (In Russ.). https://doi.org/10.17116/patol20198106163
Bi J, Li P, Li C, He J, Wang Y, Zhang H, Fan X, Jia R, Ge S. The SDF-1/CXCR4 chemokine axis in uveal melanoma cell proliferation and migration. Tumour Biol. 2016;37(3):4175-4182. https://doi.org/10.1007/s13277-015-4259-4
Franco R, Botti G, Mascolo M, Loquercio G, Liguori G, Ilardi G, Losito S, Mura AL, Calemma R, Ierano C, Bryce J, D’Alterio C, Scalaet S. CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression. Front Biosci (Elite Ed). 2010;2:13-21. https://doi.org/10.2741/e60
Nagarkatti-Gude N, Bronkhorst IH, van Duinen SG, Luyten GP, Jager MJ. Cytokines and chemokines in the vitreous fluid of eyes with uveal melanoma. Invest Ophthalmol Vis Sci. 2012;53:6748-6755. https://doi.org/10.1167/iovs.12-10123
Klinicheskie rekomendatsii «Uveal’naya melanoma», 2020. Accessed 15.06.21. (In Russ.). https://oncology-association.ru/wp-content/uploads/2020/09/uvealnaja_melanoma.pdf
Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 2017;11:279-289. https://doi.org/10.2147/OPTH.S89591
Caminal JM, Ribes J, Cleries R, Ibáñez N, Arias L, Piulats JM, Pera J, Gutierrez C, Arruga J. Relative survival of patients with uveal melanoma managed in a single center. Melanoma Res. 2012;22:271-277. https://doi.org/10.1097/CMR.0b013e328353ef30
Saakyan SV, Amiryan AG, Tsygankov AYu, Sklyarova NV, Zaletaev DV. Clinical, pathological and molecular genetic features of uveal melanoma with a high risk of metastasis. Rossiyskiy oftal’mologicheskiy zhurnal. 2015;8(2):47-52. (In Russ.).
Hanahan D, Weinberg RA. The Hallmarks of Cancer. Cell. 2000;100:57-70. https://doi.org/10.1016/s0092-8674(00)81683-9
Wang JM, Chertov O, Proost P, Li JJ, Menton P, Xu L, Sozzani S, Mantovani A, Gong W, Schirrmacher V, van Damme J, Oppenheim JJ. Purification and identification of chemokines potentially involved in kidney-specific metastasis by a murine lymphoma variant: induction of migration and NFkB activation. Int J Cancer. 1998;75:900-907. https://doi.org/10.1002/(sici)1097-0215(19980316)75:6<900::aid-ijc13>3.0.co;2-6 "> 3.0.co;2-6" target="_blank">https://doi.org/10.1002/(sici)1097-0215(19980316)75:6<900::aid-ijc13>3.0.co;2-6
Likhvantseva VG. he role of cytokines in the pathogenesis and prognosis of uveal melanoma. Tsitokiny i vospalenie. 2002;1(4):27-33. (In Russ.).
Lattanzio L, Tonissi F, Torta I, Gianello L, Russi E, Milano G, Merlano M, Nigro CL. Role of IL-8 induced angiogenesis in uveal melanoma. Invest New Drugs. 2013;31:1107-1114. https://doi.org/10.1007/s10637-013-0005-1
Lee CS, Jun IH, Kim TI, Byeon SH, Koh HJ, Lee SC. Expression of 12 cytokines in aqueous humour of uveal melanoma before and after combined Ruthenium-106 brachytherapy and transpupillary thermotherapy. Acta Ophthalmol. 2012;90:314-320. https://doi.org/10.1111/j.1755-3768.2012.02392.x
Ly LV, Bronkhorst IH, van Beelen E, Vrolijk J, Taylor AW, Versluis M, Luyten GPM, Jager MJ. Inflammatory cytokines in eyes with uveal melanoma and relation with macrophage infiltration. Invest Ophthalmol Vis Sci. 2010; 51:5445-5451. https://doi.org/10.1167/iovs.10-5526
Koga M, Kai H, Egami K, Murohara T, Ikeda A, Yasuoka S, Egashira K, Matsuishi T, Kai M, Kataoka Y, Kuwano M, Imaizumi T. Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in mice. Biochem Biophys Res Commun. 2008;365:279-284. https://doi.org/10.1016/j.bbrc.2007.10.182
Slepova OS, Kalamkarov GR, Slavinskaya NS, Bykovskaya GN, Kushnir VN, Katargina LA, Shevchenko TF, Ostrovskiy MA. Patent RF na izobretenie №2148260/12.10.1998. Byul. №33. Sposob prognozirovaniya riska zabolevaniy vtorogo glaza pri endogennykh uveitakh [RF patent for invention №2148260/12.10.1998. Bul. No. 33. A method for predicting the risk of diseases of the second eye in endogenous uveitis]. Accessed 22.04.20. (In Russ.). https://yandex.ru/patents/doc/RU2148260C1_20000427
Stein-Streilein J, Streilein JW. Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy. Int Rev Immunol. 2002;21:123-152. https://doi.org/10.1080/08830180212066
Ashour HM, Niederkorn JY. Peripheral tolerance via the anterior chamber of the eye: role of B cells in MHC class I and II antigen presentation. J Immunol. 2006;176(10):5950-5957. https://doi.org/10.4049/jimmunol.176.10.5950
Claudio L, Martiney JA, Brosnan CF. Ultrastructural studies of the blood-retina barrier after exposure to interleukin-1 beta or tumor necrosis factor-alpha. Laboratory Investigation. J Techn Meth Pathol. 1994;70(6):850-861.